10x Genomics (TXG)
(Delayed Data from NSDQ)
$14.86 USD
-0.88 (-5.59%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $14.90 +0.04 (0.27%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.86 USD
-0.88 (-5.59%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $14.90 +0.04 (0.27%) 7:58 PM ET
1-Strong Buy of 5 1
D Value A Growth C Momentum B VGM
Zacks News
Wall Street Analysts See a 27% Upside in 10x Genomics (TXG): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for 10x Genomics (TXG) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
by Zacks Equity Research
Zacks Industry Outlook Highlights: 10x Genomics, Omnicell, Inspire Medical Systems and Cerner
Buy 3 Medical Info Systems Stocks to Brave Industry-wide Challenges
by Urmimala Biswas
Stocks like 10x Genomics Inc. (TXG), Omnicell, Inc. (OMCL) and Inspire Medical Systems, Inc. (INSP) are expected to gain despite pandemic-led disruptions.
Here's Why 10x Genomics (TXG) is Poised for a Turnaround After Losing 22.3% in 4 Weeks
by Zacks Equity Research
10x Genomics (TXG) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
10x Genomics (TXG) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 61.54% and 2.25%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products' Aug 4 Earnings Roster: MCK, ABC & More
by Trina Mukherjee
The Medical Product companies' second-quarter results are likely to reflect robust earnings and revenue growth on solid base business recovery.
Will 10x Genomics (TXG) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
High-Growth Stocks Jump Back Into Investors' Favor
by Daniel Laboe
The short-term bottom for next-generation enterprises is in, and high multiple stocks are returning to investors' favor.
Strength Seen in 10x Genomics (TXG): Can Its 3.9% Jump Turn into More Strength?
by Zacks Equity Research
10x Genomics (TXG) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 56.00% and 2.99%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: 10x Genomics (TXG) Q1 Earnings Expected to Decline
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: 10x Genomics (TXG) Q4 Earnings Expected to Decline
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 0.00% and 14.53%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
10x Genomics (TXG) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should First Trust Mid Cap Growth AlphaDEX ETF (FNY) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FNY
Illumina-CDGN Partner to Create Coronavirus Tracking System
by Zacks Equity Research
Illumina (ILMN) partners with Australia's CDGN to track the national transmission of the virus causing COVID-19.
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
by Zacks Equity Research
The Zacks Analyst Blog Highlights: 10x Genomics, Allscripts Healthcare and NextGen Healthcare
3 Med Info Stocks to Improve Portfolio Health Amid Coronavirus Woes
by Urmimala Biswas
Postponement of elective surgeries leading to lower product bookings cloud Zacks-Medical Info Systems industry prospects. However, coronavirus-led demand for contactless services should aid the space. TXG, MDRX, NXGN should be the forerunners.
10x Genomics (TXG) Looks Good: Stock Adds 6.2% in Session
by Zacks Equity Research
10x Genomics (TXG) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More
by Zacks Equity Research
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.